Published online before print April 7, 2008, doi: 10.1161/CIRCULATIONAHA.107.188965
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:2544-2565.)
© 2008 American Heart Association, Inc.
AHA Scientific Statement |
Prevention of Heart Failure
A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group
The increase in heart failure (HF) rates throughout the developed and developing regions of the world poses enormous challenges for caregivers, researchers, and policymakers. Therefore, prevention of this global scourge deserves high priority. Identifying and preventing the well-recognized illnesses that lead to HF, including hypertension and coronary heart disease, should be paramount among the approaches to prevent HF. Aggressive implementation of evidence-based management of risk factors for coronary heart disease should be at the core of HF prevention strategies. Questions currently in need of attention include how to identify and treat patients with asymptomatic left ventricular systolic dysfunction (Stage B HF) and how to prevent its development. The relationship of chronic kidney disease to HF and control of chronic kidney disease in prevention of HF need further investigation. Currently, we have limited understanding of the pathophysiological basis of HF in patients with preserved left ventricular systolic function and management techniques to prevent it. New developments in the field of biomarker identification have opened possibilities for the early detection of individuals at risk for developing HF (Stage A HF). Patient groups meriting special interest include the elderly, women, and ethnic/racial minorities.
Future research ought to focus on obtaining a much better knowledge of genetics and HF, especially both genetic risk factors for development of HF and genetic markers as tools to guide prevention. Lastly, a national awareness campaign should be created and implemented to increase public awareness of HF and the importance of its prevention. Heightened public awareness will provide a platform for advocacy to create national research programs and healthcare policies dedicated to the prevention of HF.
Key Words: AHA Scientific Statements • heart failure • prevention • left ventricular dysfunction • genetics • awareness
This article has been cited by other articles:
 |
|
 |
|
  F. Zannad, N. Agrinier, and F. Alla Heart failure burden and therapy Europace, November 1, 2009; 11(suppl_5): v1 - v9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Levitan, A. Wolk, and M. A. Mittleman Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men Eur. Heart J., June 2, 2009; 30(12): 1495 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Levitan, A. Wolk, and M. A. Mittleman Consistency With the DASH Diet and Incidence of Heart Failure Arch Intern Med, May 11, 2009; 169(9): 851 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bibbins-Domingo, M. J. Pletcher, F. Lin, E. Vittinghoff, J. M. Gardin, A. Arynchyn, C. E. Lewis, O. D. Williams, and S. B. Hulley Racial Differences in Incident Heart Failure among Young Adults N. Engl. J. Med., March 19, 2009; 360(12): 1179 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heymans, E. Hirsch, S. D. Anker, P. Aukrust, J.-L. Balligand, J. W. Cohen-Tervaert, H. Drexler, G. Filippatos, S. B. Felix, L. Gullestad, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, February 1, 2009; 11(2): 119 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E A Bocchi, G Guimaraes, F Tarasoutshi, G Spina, S Mangini, and F Bacal Cardiomyopathy, adult valve disease and heart failure in South America Heart, February 1, 2009; 95(3): 181 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pfisterer, P. Buser, H. Rickli, M. Gutmann, P. Erne, P. Rickenbacher, A. Vuillomenet, U. Jeker, P. Dubach, H. Beer, et al. BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial JAMA, January 28, 2009; 301(4): 383 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Folsom, K. Yamagishi, A. Hozawa, L. E. Chambless, and for the Atherosclerosis Risk in Communities Study Absolute and Attributable Risks of Heart Failure Incidence in Relation to Optimal Risk Factors Circ Heart Fail, January 1, 2009; 2(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1671 - 1678. [Full Text] [PDF]
|
|
|
|
|
|
J. Butler and A. Kalogeropoulos Worsening Heart Failure Hospitalization Epidemic: We Do Not Know How to Prevent and We Do Not Know How to Treat! J. Am. Coll. Cardiol., August 5, 2008; 52(6): 435 - 437. [Full Text] [PDF]
|
|
|
|
 |
|
 Prevention of Heart Failure Journal Watch Cardiology, May 21, 2008; 2008(521): 1 - 1. [Full Text]
|
|